Oncolytic Virus Therapy Market Analysis

Therapy Type (HSV-based, Adenovirus-based, Reovirus, Poxviruses, NDV)

The HSV-based oncolytic virus therapy market is estimated to gain a robust revenue share of about 30% in the coming years owing to the large number of clinical trials ongoing related to HSV-based viruses. For instance, HSV has two existing variants:  HSV Type 1 (HSV-1) and HSV Type 2 (HSV-2). Among these two existing variants HSV-1 has been widely investigated in cancer oncolytic viral therapy. Approximately, 58% of the U.S. population and around 67% of the global population have evidence of exposure to HSV-1 at the same point during their lifetime. Furthermore, genomic manipulation, cytotoxicity, pathogenicity, and the availability of antiviral drugs have resulted in the growing demand for oncolytic HSV-1 widely as a therapeutic approach to melanoma.

End-User (Hospitals, Specialty Clinics, Cancer Research Institutes)

The hospitals segment in the oncolytic virus therapy market is set to garner a notable share in near future as most of the patients approach these facilities for the treatment. Patients with diseases such as cancer, when receiving an early diagnosis in hospitals, their survival rate and chances for successful treatment increase significantly. Within the hospital premises round the clock healthcare professionals including medical oncologists, and other specialists are available to help patients with cancer in the treatment planning.

Our in-depth analysis of the global market includes the following segments: